AngioDynamics Inc. Reports Strong Q1 2026 Earnings and Raises FY26 Guidance
AngioDynamics Inc. (NASDAQ: ANGO) announced its first‑quarter fiscal 2026 results on Thursday, October 2, 2025, and subsequently increased its revenue and earnings‑per‑share (EPS) outlook for the full year. The company’s stock reacted positively, gaining between 8 % and 11 % in intraday trading.
Q1 2026 Financial Highlights
| Metric | Q1 2026 | Q1 2025 | % Change |
|---|---|---|---|
| Revenue | $313 million | $279 million | +12.2 % |
| EPS | –$0.02 | –$0.08 | +75 % improvement |
| Gross Margin | 54 % | 51 % | +3 pp |
| Operating Margin | 10 % | 8 % | +2 pp |
The results were driven primarily by the Med‑Tech segment, which reported a 26 % year‑over‑year increase in sales. This growth was attributed to higher demand for angiographic and hemodialysis catheters and image‑guided vascular access products. The company also highlighted operational efficiencies that helped offset challenges in the broader health‑care equipment sector.
Revised FY26 Guidance
During the earnings call, AngioDynamics raised its fiscal 2026 revenue forecast to $1.26 billion, up from the prior $1.23 billion projection. The company also revised its EPS outlook from –$0.04 to $0.02, signaling a return to profitability for the year. Management emphasized that the Med‑Tech segment is expected to remain the primary growth driver, supported by ongoing product innovation and expanding market share.
Market Reaction
The announcement was immediately reflected in the market. Shares of AngioDynamics closed the day at $11.07, up from $10.30 at the opening bell, representing an intraday gain of approximately 8 %. Analyst coverage noted that the upward revision in guidance, coupled with stronger-than‑expected Q1 sales, underpinned the positive price movement. The company’s market capitalization remains at $438 million, with a price‑earnings ratio of –13.45 as of the latest close.
Contextual Overview
AngioDynamics, headquartered in Latham, New York, specializes in therapeutic and diagnostic devices for interventional physicians treating peripheral vascular and non‑coronary diseases. Its product portfolio includes angiographic and hemodialysis catheters, image‑guided vascular access products, and thrombolytics. The company trades on the Nasdaq exchange in U.S. dollars.
The broader Nasdaq composite index experienced modest gains on the day, rising 0.32 % to 22,826.89 points, reflecting a generally positive market environment for technology and health‑care equipment stocks.
Conclusion
AngioDynamics’ first‑quarter results demonstrate a clear turnaround in its Med‑Tech business, translating into stronger revenue growth and improved profitability metrics. The upward revision of FY26 guidance suggests confidence in sustained demand for its product lines. Market participants responded favorably, reflected in the stock’s intraday rally.
